These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 17804436)

  • 1. Structure-based calculation of drug efficiency indices.
    Hetényi C; Maran U; García-Sosa AT; Karelson M
    Bioinformatics; 2007 Oct; 23(20):2678-85. PubMed ID: 17804436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of a modified scoring function with two-dimensional descriptors for calculation of binding affinities of bulky, flexible ligands to proteins.
    Hetényi C; Paragi G; Maran U; Timár Z; Karelson M; Penke B
    J Am Chem Soc; 2006 Feb; 128(4):1233-9. PubMed ID: 16433540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular modeling of hydration in drug design.
    Mancera RL
    Curr Opin Drug Discov Devel; 2007 May; 10(3):275-80. PubMed ID: 17554853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lead optimization via high-throughput molecular docking.
    Joseph-McCarthy D; Baber JC; Feyfant E; Thompson DC; Humblet C
    Curr Opin Drug Discov Devel; 2007 May; 10(3):264-74. PubMed ID: 17554852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physics-based methods for studying protein-ligand interactions.
    Huang N; Jacobson MP
    Curr Opin Drug Discov Devel; 2007 May; 10(3):325-31. PubMed ID: 17554859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Automatic clustering of docking poses in virtual screening process using self-organizing map.
    Bouvier G; Evrard-Todeschi N; Girault JP; Bertho G
    Bioinformatics; 2010 Jan; 26(1):53-60. PubMed ID: 19910307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based maximal affinity model predicts small-molecule druggability.
    Cheng AC; Coleman RG; Smyth KT; Cao Q; Soulard P; Caffrey DR; Salzberg AC; Huang ES
    Nat Biotechnol; 2007 Jan; 25(1):71-5. PubMed ID: 17211405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Informatics and modeling challenges in fragment-based drug discovery.
    Hubbard RE; Chen I; Davis B
    Curr Opin Drug Discov Devel; 2007 May; 10(3):289-97. PubMed ID: 17554855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel class of Hsp90 inhibitors isolated by structure-based virtual screening.
    Park H; Kim YJ; Hahn JS
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6345-9. PubMed ID: 17869098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ranking poses in structure-based lead discovery and optimization: current trends in scoring function development.
    Rajamani R; Good AC
    Curr Opin Drug Discov Devel; 2007 May; 10(3):308-15. PubMed ID: 17554857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative assessment of scoring functions on a diverse test set.
    Cheng T; Li X; Li Y; Liu Z; Wang R
    J Chem Inf Model; 2009 Apr; 49(4):1079-93. PubMed ID: 19358517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond the virtual screening paradigm: structure-based searching for new lead compounds.
    Schlosser J; Rarey M
    J Chem Inf Model; 2009 Apr; 49(4):800-9. PubMed ID: 19354328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Druggability indices for protein targets derived from NMR-based screening data.
    Hajduk PJ; Huth JR; Fesik SW
    J Med Chem; 2005 Apr; 48(7):2518-25. PubMed ID: 15801841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of protein-ligand interaction fingerprints in docking.
    Brewerton SC
    Curr Opin Drug Discov Devel; 2008 May; 11(3):356-64. PubMed ID: 18428089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fragment-based lead discovery: a chemical update.
    Erlanson DA
    Curr Opin Biotechnol; 2006 Dec; 17(6):643-52. PubMed ID: 17084612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico fragment screening by replica generation (FSRG) method for fragment-based drug design.
    Fukunishi Y; Mashimo T; Orita M; Ohno K; Nakamura H
    J Chem Inf Model; 2009 Apr; 49(4):925-33. PubMed ID: 19354203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virtual screening strategies in drug discovery.
    McInnes C
    Curr Opin Chem Biol; 2007 Oct; 11(5):494-502. PubMed ID: 17936059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
    Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
    J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced virtual screening by combined use of two docking methods: getting the most on a limited budget.
    Maiorov V; Sheridan RP
    J Chem Inf Model; 2005; 45(4):1017-23. PubMed ID: 16045296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.